# A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity

> **NCT03261167** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 124 (actual)

## Conditions studied

- Spasticity, Post-Stroke

## Interventions

- **DRUG:** Botulinum toxin A (GSK1358820)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03261167
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-02
- **Primary completion:** 2018-03-20
- **Final completion:** 2019-01-10
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2020-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03261167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03261167, "A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03261167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*